1072027-36-1

Basic information

• Product Name: 4-(4-Boc-1-piperazinyl)-5-broMo-7H-pyrrolo[2,3-d]pyriMidine
• Synonyms: 4-(4-Boc-1-piperazinyl)-5-broMo-7H-pyrrolo[2,3-d]pyriMidine;tert-butyl 4-(5-bromo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazine-1-carboxylate
• CAS NO: 1072027-36-1
• Molecular Formula: C₁₅H₂₀BrN₅O₂
• Molecular Weight: 382.2556
• Mol File: 1072027-36-1.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.498±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 12.19±0.50(Predicted)
• CAS DataBase Reference: 4-(4-Boc-1-piperazinyl)-5-broMo-7H-pyrrolo[2,3-d]pyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Boc-1-piperazinyl)-5-broMo-7H-pyrrolo[2,3-d]pyriMidine(1072027-36-1)
• EPA Substance Registry System: 4-(4-Boc-1-piperazinyl)-5-broMo-7H-pyrrolo[2,3-d]pyriMidine(1072027-36-1)

Safety Data

• Hazardous Substances Data: 1072027-36-1(Hazardous Substances Data)

Usage

Description

4-(4-Boc-1-piperazinyl)-5-bromo-7H-pyrrolo[2,3-d]pyrimidine is a chemical compound characterized by its unique molecular structure, which features a pyrrolo[2,3-d]pyrimidine core with a 4-Boc-1-piperazinyl substituent and a bromine atom at the 5th position. 4-(4-Boc-1-piperazinyl)-5-broMo-7H-pyrrolo[2,3-d]pyriMidine is of interest in the field of medicinal chemistry due to its potential applications in the development of therapeutic agents.

Uses

Used in Pharmaceutical Industry:
4-(4-Boc-1-piperazinyl)-5-bromo-7H-pyrrolo[2,3-d]pyrimidine is used as a reactant for the preparation of 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives. These derivatives are known to act as Akt inhibitors, which are important in the development of antiproliferative agents. Akt, also known as protein kinase B, plays a crucial role in cell survival, growth, and proliferation. Inhibiting Akt activity can lead to the suppression of tumor growth, making these derivatives potential candidates for cancer treatment.
The compound's use in the pharmaceutical industry is primarily focused on its role as a building block for the synthesis of Akt inhibitors. These inhibitors can be further optimized and developed into more potent and selective drugs for the treatment of various types of cancer. The antiproliferative effects of these derivatives make them valuable tools in the fight against cancer, as they can help to slow down or stop the uncontrolled growth of cancer cells.

Upstream product

• 22276-95-5 5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1072027-24-7 N-[4-(5-ethyl-[1,3,4]thiadiazol-2-ylsulfamoyl)-phenyl]-4-[5-((S)-3-fluoro-pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-piperazine-1-carbothioamide 
• 1072027-42-9 C₂₁H₂₃ClFN₇S 

Relevant articles and documents

Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity

Targeting of Akt has been validated as a well rationalized approach to cancer treatment, and represents a promising therapeutic strategy for aggressive hematologic malignancies. We describe herein an exploration of novel Akt inhibitors for cancer therapy through structural optimization of previously described 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives. Our studies yielded a novel series of pyrrolopyrimidine based phenylpiperidine carboxamides capable of potent inhibition of Akt1. Notably, 10h exhibited robust antiproliferative effects in both mantle cell lymphoma cell lines and primary patient tumor cells. Low micromolar doses of 10h induced cell apoptosis and cell cycle arrest in G2/M phase, and significantly downregulated the phosphorylation of Akt downstream effectors GSK3β and S6 in Jeko-1 cells.

Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity

Continuous optimization of benzylic substituents on 1-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-1-yl)-2-phenylethan-1-one structure as Akt inhibitors was described in this paper. Particularly, compounds 8 and 14g exhibited high enzymatic potency against all Akt isoforms and antiproliferative effects in mantle cell lymphoma cell lines, as well as favorable cytotoxicities in patient primary cancer cells. Low micromolar doses of both 8 and 14g dose-dependently induced cell apoptosis and G2/M cell cycle arrest, also suppressed the phosphorylation level of Akt downstream targets GSK3β and S6.

Substituted p-chlorophenyl acetylpiperazine-containing compound as well as preparation method and application thereof

The application provides a substituted p-chlorophenyl acetylpiperazine-containing compound as well as a preparation method and application of the substituted p-chlorophenyl acetylpiperazine-containingcompound. The compound has the structure shown in the formula (I), and has better Akt1 inhibitory activity or growth inhibitory activity to MCL cell lines.